Enthesitis-related juvenile idiopathic arthritis
MONDO:0019437Enthesitis-related juvenile idiopathic arthritis is a subtype of juvenile idiopathic arthritis that is characterized by both arthritis and inflammation of an enthesitis site (the point at which a ligament, tendon, or joint capsule attaches to the bone). Signs and symptoms generally develop in late childhood or early adolescence and include pain, tenderness, and swelling in joints and at the enthesis. The knee and the back of the ankle (at the Achilles tendon) are the most commonly affected parts of the body. The underlying cause of enthesitis-related juvenile idiopathic arthritis is currently unknown (idiopathic). It is very rare for more than one member of a family to have juvenile arthritis; however, research suggests that having a family member with juvenile arthritis or any autoimmune disease may increase the risk of having juvenile arthritis, in general. Treatment usually involves different types of medications to help manage symptoms and/or physical therapy.
Also known as: ERA, enthesitis-related JIA, era, enthesitis related arthritis, juvenile, enthesitis-related arthritis, juvenile enthesitis-related arthritis, juvenile spondylarthropathy
31 clinical trials for this condition and its sub-types, 7 tagged with Enthesitis-related juvenile idiopathic arthritis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for kids with arthritis: drug trial shows promise
Disease control OngoingThis study tests whether the drug ixekizumab is safe and effective for children with certain types of juvenile arthritis (enthesitis-related arthritis and juvenile psoriatic arthritis). About 101 children aged 2 to 17 years will receive either ixekizumab or the standard drug adal…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a biologic drug tame juvenile arthritis in kids?
Knowledge-focused CancelledThis study follows children aged 6 to 17 with active juvenile enthesitis-related or psoriatic arthritis who are being treated with secukinumab. Researchers will track how long children stay on the drug, how much their symptoms improve, and whether they achieve remission. The goal…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC